Lipoprotein Levels Following Treatment with Cyproterone Acetate or LHRH Analogues

D. A. GILLATT; C. H. BOLTON; D. CHADWICK; L. G. DOWNS; M. I. HOPTON; J. C. GINGELL

doi:10.1111/j.1464-410X.1993.tb16074.x

Lipoprotein Levels Following Treatment with Cyproterone Acetate or LHRH Analogues

D. A. GILLATT^*, C. H. BOLTON, D. CHADWICK, L. G. DOWNS, M. I. HOPTON, J. C. GINGELL

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Summary— Fasting serum lipoproteins were measured in patients with carcinoma of the prostate. Twelve patients were on no hormonal treatment (Group 1). Fifteen were on cyproterone acetate (Group 3), 17 were on the long‐acting LHRH analogue Zoladex (Group 4) and 11 on a combination of cyproterone acetate and Zoladex (group 5). In addition, 27 patients with benign urological disease were taken as controls (Group 2). In both groups in which cyproterone acetate was part of the treatment the total high density lipoprotein cholesterol levels were significantly lower than in the other groups. Patients on cyproterone acetate alone had significantly higher levels of very low density lipoprotein (VLDL) triglyceride levels than those not on cyproterone acetate. These results confirm changes in serum lipoprotein levels in patients taking cyproterone acetate and these changes may have potential adverse effects if the treatment is prolonged.

Original language	English
Pages (from-to)	728-730
Number of pages	3
Journal	British Journal of Urology
Volume	71
Issue number	6
DOIs	https://doi.org/10.1111/j.1464-410X.1993.tb16074.x
Publication status	Published - 1993
Externally published	Yes

Access to Document

10.1111/j.1464-410X.1993.tb16074.x

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Lipoprotein Levels Following Treatment with Cyproterone Acetate or LHRH Analogues'. Together they form a unique fingerprint.

Cite this

@article{dab2d24a6e3646e9985f52113bdc658c,

title = "Lipoprotein Levels Following Treatment with Cyproterone Acetate or LHRH Analogues",

abstract = "Summary— Fasting serum lipoproteins were measured in patients with carcinoma of the prostate. Twelve patients were on no hormonal treatment (Group 1). Fifteen were on cyproterone acetate (Group 3), 17 were on the long‐acting LHRH analogue Zoladex (Group 4) and 11 on a combination of cyproterone acetate and Zoladex (group 5). In addition, 27 patients with benign urological disease were taken as controls (Group 2). In both groups in which cyproterone acetate was part of the treatment the total high density lipoprotein cholesterol levels were significantly lower than in the other groups. Patients on cyproterone acetate alone had significantly higher levels of very low density lipoprotein (VLDL) triglyceride levels than those not on cyproterone acetate. These results confirm changes in serum lipoprotein levels in patients taking cyproterone acetate and these changes may have potential adverse effects if the treatment is prolonged.",

author = "GILLATT, {D. A.} and BOLTON, {C. H.} and D. CHADWICK and DOWNS, {L. G.} and HOPTON, {M. I.} and GINGELL, {J. C.}",

year = "1993",

doi = "10.1111/j.1464-410X.1993.tb16074.x",

language = "English",

volume = "71",

pages = "728--730",

journal = "British Journal of Urology",

issn = "1464-4096",

publisher = "Wiley-Blackwell, Wiley",

number = "6",

}

TY - JOUR

T1 - Lipoprotein Levels Following Treatment with Cyproterone Acetate or LHRH Analogues

AU - GILLATT, D. A.

AU - BOLTON, C. H.

AU - CHADWICK, D.

AU - DOWNS, L. G.

AU - HOPTON, M. I.

AU - GINGELL, J. C.

PY - 1993

Y1 - 1993

N2 - Summary— Fasting serum lipoproteins were measured in patients with carcinoma of the prostate. Twelve patients were on no hormonal treatment (Group 1). Fifteen were on cyproterone acetate (Group 3), 17 were on the long‐acting LHRH analogue Zoladex (Group 4) and 11 on a combination of cyproterone acetate and Zoladex (group 5). In addition, 27 patients with benign urological disease were taken as controls (Group 2). In both groups in which cyproterone acetate was part of the treatment the total high density lipoprotein cholesterol levels were significantly lower than in the other groups. Patients on cyproterone acetate alone had significantly higher levels of very low density lipoprotein (VLDL) triglyceride levels than those not on cyproterone acetate. These results confirm changes in serum lipoprotein levels in patients taking cyproterone acetate and these changes may have potential adverse effects if the treatment is prolonged.

AB - Summary— Fasting serum lipoproteins were measured in patients with carcinoma of the prostate. Twelve patients were on no hormonal treatment (Group 1). Fifteen were on cyproterone acetate (Group 3), 17 were on the long‐acting LHRH analogue Zoladex (Group 4) and 11 on a combination of cyproterone acetate and Zoladex (group 5). In addition, 27 patients with benign urological disease were taken as controls (Group 2). In both groups in which cyproterone acetate was part of the treatment the total high density lipoprotein cholesterol levels were significantly lower than in the other groups. Patients on cyproterone acetate alone had significantly higher levels of very low density lipoprotein (VLDL) triglyceride levels than those not on cyproterone acetate. These results confirm changes in serum lipoprotein levels in patients taking cyproterone acetate and these changes may have potential adverse effects if the treatment is prolonged.

UR - http://www.scopus.com/inward/record.url?scp=0027195395&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.1993.tb16074.x

DO - 10.1111/j.1464-410X.1993.tb16074.x

M3 - Article

C2 - 8343902

AN - SCOPUS:0027195395

VL - 71

SP - 728

EP - 730

JO - British Journal of Urology

JF - British Journal of Urology

SN - 1464-4096

IS - 6

ER -